Inform GenomicsTransplant Product Shown to Predict Oral Mucositis with a High Degree of Accuracy in Patients Undergoing Conditioning Regimens Prior to Hematopoetic Stem Cell Transplant

Published: Dec 11, 2012

Boston, MA, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a private company focused on developing novel platforms of genomic-based personalized medicine products for cancer supportive care, presented results that demonstrate the ability of its Transplant Product to predict a patient's risk for developing oral mucositis (OM) prior to high dose chemotherapy as part of conditioning regimens for stem cell transplant in patients with hematologic malignancies.

Back to news